肥厚型心肌病最新研究进展
Recent Advances in Hypertrophic Cardiomyopathy
DOI: 10.12677/ACM.2023.132337, PDF,    科研立项经费支持
作者: 路 旗：济宁医学院临床医学院，山东 济宁；李传方, 甘立军*：济宁医学院附属医院心血管内科，山东 济宁
关键词: 肥厚型心肌病；基因突变；临床特征；诊断；治疗；Hypertrophic Cardiomyopathy； Gene Mutation； Clinical Manifestations； Diagnosis； Treatment
摘要: 肥厚型心肌病(hypertrophic cardiomyopathy, HCM)是目前最常见的遗传性心脏病之一，也是青少年和运动员猝死的主要原因之一。它以左心室壁肥厚和室间隔不对称性肥厚为主要特征，亦可表现为心尖肥厚，并且根据肥厚的严重程度，HCM患者可出现左室流出道梗阻(LVOTO)、舒张功能障碍、心房颤动和心力衰竭等表现。近年来随着基因分子等技术的发展，人们对于HCM的认识有了明显提高，笔者现就肥厚型心肌病的最新研究进展予以综述。
Abstract: Hypertrophic cardiomyopathy (HCM) is one of the most common hereditary heart diseases, and is one of the main causes of sudden death in adolescents and athletes. It is mainly characterized by left ventricular wall hypertrophy and asymmetrical ventricular septum hypertrophy, as well as apex hypertrophy, and depending on the severity of hypertrophy, HCM patients may present with left ventricular outflow tract obstruction (LVOTO), diastolic dysfunction, atrial fibrillation, and heart failure. In recent years, with the development of gene and molecular technology, people’s under-standing of HCM has been improved significantly. This article reviews the latest research progress of hypertrophic cardiomyopathy.
文章引用：路旗, 李传方, 甘立军. 肥厚型心肌病最新研究进展[J]. 临床医学进展, 2023, 13(2): 2397-2402. https://doi.org/10.12677/ACM.2023.132337

参考文献

[1] Maron, B.J., Desai, M.Y., Nishimura, R.A., et al. (2022) Management of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review. Journal of the American College of Cardiology, 79, 390-414. [Google Scholar] [CrossRef] [PubMed]
[2] Batzner, A. and Seggewiß, H. (2020) Hypertrophe Kardiomyopa-thie [Hypertrophic Cardiomyopathy]. Herz, 45, 233-242. [Google Scholar] [CrossRef] [PubMed]
[3] Semsarian, C., Ingles, J., Maron, M.S., et al. (2015) New Per-spectives on the Prevalence of Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 65, 1249-1254. [Google Scholar] [CrossRef] [PubMed]
[4] Younger, J., Lo, A., McCormack, L., et al. (2020) Hy-pertrophic Cardiomyopathy: Challenging the Status Quo? Heart, Lung and Circulation, 29, 556-565. [Google Scholar] [CrossRef] [PubMed]
[5] Butters, A., Semsarian, C.R., Bagnall, R.D., et al. (2021) Clinical Profile and Health Disparities in a Multiethnic Cohort of Patients with Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 14, e007537. [Google Scholar] [CrossRef] 
[6] Geske, J.B., Ong, K.C., Siontis, K.C., et al. (2017) Women with Hypertrophic Cardiomyopathy Have Worse Survival. European Heart Journal, 38, 3434-3440. [Google Scholar] [CrossRef] [PubMed]
[7] Teekakirikul, P., Padera, R.F., Seidman, J.G. and Seidman, C.E. (2012) Hypertrophic Cardiomyopathy: Translating Cellular Cross Talk into Therapeutics. Journal of Cell Biology, 199, 417-421. [Google Scholar] [CrossRef] [PubMed]
[8] Teekakirikul, P., Zhu, W., Huang, H.C. and Fung, E. (2019) Hypertrophic Cardiomyopathy: An Overview of Genetics and Management. Biomolecules, 9, Article No. 878. [Google Scholar] [CrossRef] [PubMed]
[9] Goldspink, P.H., Warren, C.M., Kitajewski, J., Wolska, B.M. and So-laro, R.J. (2021) A Perspective on Personalized Therapies in Hypertrophic Cardiomyopathy. Journal of Cardiovascular Pharmacology, 77, 317-322. [Google Scholar] [CrossRef] 
[10] Ito, K., Patel, P.N., Gorham, J.M., et al. (2017) Identification of Pathogenic Gene Mutations in LMNA and MYBPC3 That Alter RNA Splicing. Proceedings of the National Academy of Sciences of the United States of America, 114, 7689-7694. [Google Scholar] [CrossRef] [PubMed]
[11] Coppini, R., Ferrantini, C., Mugelli, A., Poggesi, C. and Cerbai, E. (2018) Altered Ca2+ and Na+ Homeostasis in Human Hypertrophic Cardiomyopathy: Implications for Arrhythmogenesis. Frontiers in Physiology, 9, Article 1391. [Google Scholar] [CrossRef] [PubMed]
[12] Marian, A.J. and Braunwald, E. (2017) Hypertrophic Cardiomyo-pathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. Circulation Research, 121, 749-770. [Google Scholar] [CrossRef] 
[13] Sabater-Molina, M., Pérez-Sánchez, I., Hernández del Rincón, J.P. and Gimeno, J.R. (2017) Genetics of Hypertrophic Cardiomyopathy: A Review of Current State. Clinical Genetics, 93, 3-14. [Google Scholar] [CrossRef] [PubMed]
[14] Walsh, R., Thomson, K.L., Ware, J.S., et al. (2017) Re-assessment of Mendelian Gene Pathogenicity Using 7,855 Cardiomyopathy Cases and 60,706 Reference Samples. Ge-netics in Medicine, 19, 192-203. [Google Scholar] [CrossRef] [PubMed]
[15] Wooten, E.C., Hebl, V.B., Wolf, M.J., et al. (2013) Formin Homology 2 Domain Containing 3 Variants Associated with Hypertrophic Cardiomyopathy. Circulation: Cardiovascular Genetics, 6, 10-18. [Google Scholar] [CrossRef] 
[16] Ochoa, J.P., Sabater-Molina, M., García-Pinilla, J.M., et al. (2018) Formin Homology 2 Domain Containing 3 (FHOD3) Is a Genetic Basis for Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 72, 2457-2467. [Google Scholar] [CrossRef] [PubMed]
[17] Angelopoulos, A., Oikonomou, E., Vogiatzi, G., et al. (2021) Mi-croRNAs as Biomarkers in Hypertrophic Cardiomyopathy: Current State of the Art. Current Medicinal Chemistry, 28, 7400-7412. [Google Scholar] [CrossRef] [PubMed]
[18] Lioncino, M., Monda, E., Verrillo, F., et al. (2022) Hypertrophic Cardiomyopathy in RASopathies: Diagnosis, Clinical Characteristics, Prognostic Implications, and Man-agement. Heart Failure Clinics, 18, 19-29. [Google Scholar] [CrossRef] [PubMed]
[19] 邹玉宝, 宋雷. 中国成人肥厚型心肌病诊断与治疗指南解读[J]. 中国循环杂志, 2018, 33(S2): 68-73.
[20] Veselka, J., Anavekar, N.S. and Charron, P. (2017) Hypertrophic Obstruc-tive Cardiomyopathy. Lancet, 389, 1253- 1267. [Google Scholar] [CrossRef] 
[21] Chrispin, J. and Marine, J.E. (2021) Atrial Fibrillation and Hypertrophic Cardiomyopathy: More Progress Needed. Journal of Car-diovascular Electrophysiology, 32, 667-668. [Google Scholar] [CrossRef] [PubMed]
[22] Finocchiaro, G., Sheikh, N., Biagini, E., et al. (2020) The Electrocardiogram in the Diagnosis and Management of Patients with Hypertrophic Cardi-omyopathy. Heart Rhythm, 17, 142-151. [Google Scholar] [CrossRef] [PubMed]
[23] Medical Masterclass Contributors and Firth, J. (2019) Cardiology: Hypertrophic Cardiomyopathy. Clinical Medicine Journal, 19, 61-63. [Google Scholar] [CrossRef] [PubMed]
[24] Makavos, G., Κairis, C., Tselegkidi, M.-E., et al. (2019) Hyper-trophic Cardiomyopathy: An Updated Review on Diagnosis, Prognosis, and Treatment. Heart Failure Reviews, 24, 439-459. [Google Scholar] [CrossRef] [PubMed]
[25] Maron, M.S., Rowin, E.J., Lin, D., et al. (2012) Prev-alence and Clinical Profile of Myocardial Crypts in Hypertrophic Cardiomyopathy. Circulation: Cardiovascular Imaging, 5, 441-447. [Google Scholar] [CrossRef] 
[26] Rudolph, A., Abdel-Aty, H., Bohl, S., et al. (2009) Noninvasive Detection of Fibrosis Applying Contrast-Enhanced Cardiac Magnetic Resonance in Different Forms of Left Ventricular Hypertrophy Relation to Remodeling. Journal of the American College of Cardiology, 53, 284-291. [Google Scholar] [CrossRef] [PubMed]
[27] 葛均波, 徐永健, 王辰. 内科学[M]. 第9版. 北京: 人民卫生出版社, 2018: 265.
[28] Ommen, S.R., Mital, S., Burke, M.A., et al. (2020) 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients with Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/ American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 142, e533-e557. [Google Scholar] [CrossRef] 
[29] Nishimura, R.A., Seggewiss, H. and Schaff, H.V. (2017) Hypertrophic Obstructive Cardiomyopathy: Surgical Myectomy and Septal Ablation. Circulation Research, 121, 771-783. [Google Scholar] [CrossRef] 
[30] Elliott, P.M., Anastasakis, A., Borger, M.A., et al. (2014) 2014 ESC Guidelines on Diagnosis and Management of Hypertrophic Cardiomyopathy: The Task Force for the Diagno-sis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). European Heart Journal, 35, 2733-2779. [Google Scholar] [CrossRef] [PubMed]
[31] Prondzynski, M., Mearini, G. and Carrier, L. (2019) Gene Therapy Strategies in the Treatment of Hypertrophic Cardiomyopathy. Pflügers Archiv-European Journal of Physiology, 471, 807-815. [Google Scholar] [CrossRef] [PubMed]
[32] Gedicke-Hornung, C., Behrens-Gawlik, V., Reischmann, S., et al. (2013) Rescue of Cardiomyopathy through U7snRNA- Mediated Exon Skipping in Mybpc3-Targeted Knock-in Mice. EMBO Molecular Medicine, 5, 1128-1145. [Google Scholar] [CrossRef] [PubMed]
[33] Trochet, D., Prudhon, B., Beuvin, M., et al. (2018) Allele-Specific Silencing Therapy for Dynamin 2-Related Dominant Centronuclear Myopathy. EMBO Molecular Medicine, 10, 239-253. [Google Scholar] [CrossRef] [PubMed]
[34] Song, L., Su, M., Wang, S., et al. (2014) MiR-451 Is Decreased in Hypertrophic Cardiomyopathy and Regulates Autophagy by Targeting TSC1. Journal of Cellular and Molecular Medicine, 18, 2266-2274. [Google Scholar] [CrossRef] [PubMed]
[35] Green, E.M., Wakimoto, H., Anderson, R.L., et al. (2016) A Small-Molecule Inhibitor of Sarcomere Contractility Suppresses Hypertrophic Cardiomyopathy in Mice. Science, 351, 617-621. [Google Scholar] [CrossRef] [PubMed]
[36] 熊萍, 符祖丰, 钟一鸣. 肥厚型心肌病预后因素的研究进展[J]. 赣南医学院学报, 2020, 40(9): 886-890. [Google Scholar] [CrossRef] 

为你推荐